Nonhormonal Treatment of Menopausal Vaso...

Interview with Giselle Corbie, MD, MSc, Associate Editor of JAMA Internal Medicine, and Lynda H. Powell, PhD, author of Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial. Hosted by Eve Rittenberg, MD. Related Content: Lifestyle Inte ... Show More

Interview with Sammy Saab, MD, MPH, author of Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review. Hosted by Eve Rittenberg, MD. Related Content: Targeting MASLD and MASH in the US Hispanic/Latino Population 

Interview with Robert Bals, MD, PhD, author of Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial, and Dan H. Barouch, MD, PhD, author of A Novel Approach for Preventing Respiratory Virus Infections. Hosted by Eve Rittenberg, MD. R ... Show More

Interview with Bradley J. Katz, MD, PhD, author of Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide. Hosted by Neil Bressler, MD. Related Content: Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatid ... Show More

<p dir="ltr"><strong>Contributor: Travis Barlock MD</strong></p> <p dir="ltr"><strong>Educational Pearls:</strong></p> <p dir="ltr">How do you differentiate between compensated and decompensated cirrhosis?</p> <p dir="ltr">Use the acronym <strong>VIBE</strong> to look for signs o ... Show More

By the end of this episode you will be able to: Describe the anatomy and physiology of the liver Outline the pathophysiology and common symptoms of liver failure Explain how to assess and treat a patient with cirrhosis 

<div>Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as Non-alcoholic fatty liver disease (NAFLD), is estimated to affect up to 1 in 5 people in the UK. Rates are increasing with rising levels of obesity. Although most cases of MASLD are linked to exc ... Show More

Featuring articles on PI3K-altered colorectal cancer, type 2 diabetes, oral semaglutide, and proportional-assist ventilation; a review article on tumor lysis syndrome; a case report of a girl with chest pain and bone and liver lesions; and Perspectives on integrating pharmacother ... Show More

Non-alcoholic fatty liver disease (NAFLD) presents as a disease spectrum. Fatty change is a common and frequently benign condition, present in 20-30% of the population and up to 90% of the morbidly obese. This Essential Knowledge Update (EKU2017.1) podcast explores the NICE guide ... Show More

<p class="MsoNormal">An analysis of the IRIS® Registry shows IOL exchanges are increasing over time with vision improving 60% of the time, but worse visual outcomes associated with greater age, worse baseline vision, Black race, Hispanic ethnicity, Medicaid insurance, smoking, an ... Show More

Most SLPs we know can count on one hand (…or one finger!?) the number of times they learned about the liver in grad school. But when it comes to our role in cognitive-communication disorders, liver disease can be a main cause — and something you absolutely should be familiar with ... Show More

Fatty liver disease, encompassing both non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), is a prevalent condition in the United States. NAFLD affects approximately 24% of U.S. adults, translating to about 80 million individuals. Within this group, a sub ... Show More

<p>Kristin Kirkpatrick, MS, RDN, renowned dietitian from the Cleveland Clinic and author of <em>Skinny Liver</em> and <em>Regenerative Health</em> explains why the liver is critical to health, and how Non-Alcoholic Fatty Liver Disease is a silent killer that has become an epidemi ... Show More